Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Vulvodynia 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Dyspareunia 1

Interventions

Cyclophosphamide 171Docetaxel 164Paclitaxel 160Trastuzumab 152Capecitabine 130Tamoxifen 119Letrozole 105Epirubicin 93Doxorubicin 83Anastrozole 83exemestane 77Fulvestrant 75Carboplatin 64Fluorouracil 63Radiotherapy 61pertuzumab 59Gemcitabine 55Vinorelbine 43Goserelin 39eribulin 36130-nm albumin-bound paclitaxel 36palbociclib 32Bevacizumab 32ribociclib 30Zoledronic Acid 29Lapatinib 29Methotrexate 28Drug Therapy 28Chemotherapy, Adjuvant 28Ado-Trastuzumab Emtansine 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Water × Breast × Clear all
NCT04799249 2024-08-01

PRESERVE 2

G1 Therapeutics, Inc.

Phase 3 Completed
194 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01539317 2017-04-14

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

OHSU Knight Cancer Institute

Phase 3 Completed
50 enrolled 9 charts
Breast

Breast Neoplasms, Dyspareunia, Vulvodynia

NCT01479244 2017-02-27

PRESENT

Galena Biopharma, Inc.

Phase 3 Completed
758 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡